POLICY Description:
This document addresses routine testing of serum vitamin D levels in adults and children, in the absence of clinical signs and symptoms of vitamin D deficiency or intoxication or conditions for which vitamin D supplementation may be recommended. Vitamin D testing is a non-invasive blood test which can aid in the identification and clinical management of individuals at-risk for vitamin D deficiency. This document does not address testing for vitamin D in individuals who exhibit clinical manifestations or risk factors of vitamin D deficiency or toxicity. The State of Louisiana has approved the following as it relates to Screening for Vitamin D Deficiency in Average Risk Individuals:

1. The submission of a diagnosis along with the appropriate CPT Codes should be submitted for reimbursement of Vitamin D Testing. This is based upon peer review literature and review of each health plans guidelines. Population level based screening for Vitamin D Deficiency in average risk asymptomatic adults and children is not recommended;

2. The approved diagnostic list would be the List adopted by CMS

3. The limit for screenings will be no more than one per year. For members Diagnosed with Vitamin D Deficiency there will be a limit of four per year.

We will monitor how each MCO is able to stay aligned with each other as diagnosis changes occur, so as to not confuse providers.

Please submit the policy on each of your own templates for Act 319 posting requirements.

https://providers.healthybluela.com
Healthy Blue is the trade name of Community Care Health Plan of Louisiana, Inc., an independent licensee of the Blue Cross and Blue Shield Association.
BLAPEC-1996-20 [August 2020]
Clinical Indications

Not Medically Necessary:

Testing vitamin D levels in individuals with no known signs or symptoms of vitamin D deficiency or intoxication nor conditions for which vitamin D treatment is recommended is considered not medically necessary.

Coding

The following codes for treatments and procedures applicable to this guideline are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

CPT

82306  Vitamin D; 25 hydroxy, includes fraction(s), if performed [when specified as screening]
82652  Vitamin D; 1, 25 dihydroxy, includes fraction(s), if performed [when specified as screening]
0038U  Vitamin D, 25 hydroxy D2 and D3, by LCMS/MS, serum microsample, quantitative
Sensieva™ Droplet 25OH Vitamin D2/D3 Microvolume LC/MS Assay, InSource Diagnostics

The only ICD-10 codes approved for screening are listed by CMS.

https://providers.healthyblueela.com

Healthy Blue is the trade name of Community Care Health Plan of Louisiana, Inc., an independent licensee of the Blue Cross and Blue Shield Association.
BLAPEC-1996-20 [August 2020]
D deficiency testing; however, it is a poor indicator due to its efficient regulation by other vitamin and hormone levels as well as its relatively short half-life (15 hours). Generally, calcitriol levels do not decrease markedly unless an individual has a severe deficiency in vitamin D. Conversely, serum measurement of 25-hydroxyvitamin D, or calcidiol (produced by the liver), is a much more reliable indicator of vitamin D status. Although levels of calcidiol also do not correlate significantly with Vitamin D stores, it is a reflection of serum circulating levels of cutaneously produced and ingested vitamin D with a half-life averaging 15 days. Unfortunately, there is considerable disagreement regarding the serum levels of calcidiol (25-hydroxyvitamin D) that are indicative of deficiency warranting intervention, such as dietary supplementation. Further complicating medical management of Vitamin D deficiency, is the wide variability that exists in laboratory analysis methods. There are also health risks associated with excessive vitamin D levels and vitamin D toxicity, such as anorexia, weight loss, polyuria, kidney stones, and heart arrhythmias. Toxicity is most likely to result from over-supplementation (National Institutes of Health [NIH], 2016).

Despite the uncertainty that remains in clinical practice regarding not only the clinical benefit of vitamin D serum testing, but even the definition of vitamin D deficiency, screening of asymptomatic, average-risk individuals (e.g., non-pregnant, community dwelling adults without osteoporosis or chronic kidney disease), remains commonplace. A study evaluating data from the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey found that diagnosis for vitamin D deficiency more than tripled between 2008 and 2010 (383 in 2008 vs. 1177 visits per 100,000 population in 2010) (Huang, 2014).

The U.S. Preventive Services Task Force (USPSTF) has rated the current medical evidence insufficient to assess the balance of benefits and harms of screening for vitamin D deficiency in asymptomatic adults. This recommendation is specified to be applicable to “community-dwelling, non-pregnant adults aged 18 years or older who are seen in primary care settings and are not known to have signs or symptoms of vitamin D deficiency or conditions for which vitamin D treatment is recommended” (USPSTF, 2015).

The Endocrine Society published clinical practice guideline recommendations in 2011, which contain the following statement related to screening for vitamin D deficiency in both children and adults, “We recommend screening for vitamin D deficiency in individuals at risk for deficiency. We do not recommend population screening for vitamin D deficiency in individuals who are not at risk.” This recommendation is based on the Endocrine Society’s highest level of evidence and the rating denoted as ‘strong’, meaning the Task Force has confidence that individuals who receive care according to the recommendation “will derive, on average, more good than harm” (Holick, 2011).
The American Society of Clinical Pathology (ASCP, 2017) contributed the following recommendation to Choosing Wisely®.

Vitamin D deficiency is common in many populations, particularly in patients at higher latitudes, during winter months and in those with limited sun exposure. Over the counter Vitamin D supplements and increased summer sun exposure are sufficient for most otherwise healthy patients. Laboratory testing is appropriate in higher risk patients when results will be used to institute more aggressive therapy (e.g., osteoporosis, chronic kidney disease, malabsorption, some infections, obese individuals).

In summary, there are a number of conditions, some of which are aforementioned, that would place individuals at risk for development of vitamin D deficiency and merit testing of vitamin D levels for screening and management. According to the Endocrine Society’s (2011) recommendations, infants who may be at risk for vitamin D deficiency include those who are breast-fed without vitamin D supplementation, have darker pigmented skin, and those with maternal vitamin D deficiency. Adults may be at higher risk for vitamin D deficiency if their outdoor activities are greatly limited (for example, those who are institutionalized or the elderly), if they practice aggressive sun protection measures or if living in an area considered high risk. Pregnancy, lactation, obesity and certain medication regiments are additional circumstances that may place individuals at high risk for vitamin D deficiency and may warrant screening, supplementation and on-going clinical management. However, based on the current evidence and consensus recommendations, screening for vitamin D deficiency in average-risk, asymptomatic adults and children, is not recommended.

Definitions

Endogenous: To be produced or synthesized within an organism or system.

Screening: Examination of a group to separate well persons from those who have an undiagnosed pathologic condition or who are at high risk.

References

Peer Reviewed Publications:


https://providers.healthyblue-la.com
Healthy Blue is the trade name of Community Care Health Plan of Louisiana, Inc., an independent licensee of the Blue Cross and Blue Shield Association.
BLAPEC-1996-20 [August 2020]
### Government Business Division

#### Policies and Procedures

<table>
<thead>
<tr>
<th>Section (Primary Department)</th>
<th>Subject (Document Title)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Utilization Management</td>
<td>Screening for Vitamin D Deficiency in Average Risk Individuals</td>
</tr>
</tbody>
</table>


**Government Agency, Medical Society, and Other Authoritative Publications:**


Healthy Blue is the trade name of Community Care Health Plan of Louisiana, Inc., an independent licensee of the Blue Cross and Blue Shield Association.

BLAPEC-1996-20 [August 2020]
RESPONSIBLE DEPARTMENTS:

Primary Department:
Louisiana Medicaid Medical Policy

Secondary Department(s):
Louisiana Medicaid Operations

EXCEPTIONS:

This policy only applies to Louisiana

REVISION HISTORY:

<table>
<thead>
<tr>
<th>Review Date</th>
<th>Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>7/20/2020</td>
<td>• Modified Anthem Policy CG-LAB-11 for Louisiana using recommended CMS Diagnostic Codes for medical necessity determination for Vitamin D Testing.</td>
</tr>
</tbody>
</table>